METIS: Pivotal open-label randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).
The METIS trial is designed to investigate the efficacy of the NovoTTF-100M device in treating patients non-small cell lung cancer (NSCLC) with metastases to the brain. The eligible subjects must have 1 inoperable brain metastasis or 2-10 brain lesions and must be able to carry the NovoTTF-100M device. Subjects enrolled in the treatment arm of the study will wear the device for at least 18 hours a day, on average, and have study visits roughly every 2 months for 10-15 months. For additional information regarding this clinical trial visit https://www.novocuretrial.com/metis/
For more details please visit iConnect and/or email us at NCRD-BTC@uphs.upenn.edu Image retrieved from https://www.novocuretrial.com/metis/
- Study Identifier: 826343
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required